Home | Inova Search App - Admin

Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an Emergency Department Setting for Heart Failure (LANER-HF)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in an Emergency Department Setting for Heart Failure (LANER-HF)
SPHERE Uptravi® (SelexiPag): tHe usErs dRug rEgistry (SPHERE)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about SPHERE Uptravi® (SelexiPag): tHe usErs dRug rEgistry (SPHERE)

Summary

To develop and maintain a database of de-identified patient medical information and other related information in order to better assess and optimize outcomes for patients diagnosed with PAH and receiving treatment with Uptravi®. Age Group: Patients ≥ 18 years of age at time of Uptravi initiation. National Clinical Trial (NCT) identifier on clinicaltrials.gov: NCT03278002
SPOCK: Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor after Aromatase Inhibitor and CDK inhibition. A Phase II, open label, interventional trial using gene expression based biomarkers of estrogen activation in advanced

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about SPOCK: Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor after Aromatase Inhibitor and CDK inhibition. A Phase II, open label, interventional trial using gene expression based biomarkers of estrogen activation in advanced
STELLAR: Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about STELLAR: Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR)
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma (HM-085)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma (HM-085)
(STUDY CLOSED) Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about (STUDY CLOSED) Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Summary

(STUDY CLOSED) Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
(STUDY CLOSED) A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about (STUDY CLOSED) A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (STARSCAPE-OLE)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (STARSCAPE-OLE)
Study in Parkinson's Disease Patients with Dyskinesia with Combinations of JM-010 and Its Individual Components (SHINE)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Study in Parkinson's Disease Patients with Dyskinesia with Combinations of JM-010 and Its Individual Components (SHINE)
Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial (STAMP)

Submitted by centretek on Sat, 10/15/2022 - 10:29
Read more about Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial (STAMP)